Fondaparinux sodium: a review of its use in the treatment of acute venous thromboembolism.

@article{Robinson2005FondaparinuxSA,
  title={Fondaparinux sodium: a review of its use in the treatment of acute venous thromboembolism.},
  author={Dean M. Robinson and K. J. Wellington},
  journal={American journal of cardiovascular drugs : drugs, devices, and other interventions},
  year={2005},
  volume={5 5},
  pages={
          335-46
        }
}
Fondaparinux sodium (fondaparinux) is a synthetic sulfated pentasaccharide anticoagulant developed from the antithrombin binding moiety of heparin. Through the activation of antithrombin it inhibits Factor Xa, the activation of thrombin, and the subsequent coagulation cascade. Fondaparinux is approved in Europe and the US for the treatment of acute venous thromboembolism (VTE), including both deep vein thrombosis (DVT) and pulmonary embolism (PE), when used in conjunction with warfarin. In… CONTINUE READING